Effective Monotherapy with Amrubicin for a Refractory Extrapulmonary Small-Cell Carcinoma of the Liver | Zendy

Taichi Isobe | Zendy; Shunichi Yanai | Zendy; Hitoshi Kusaba | Zendy; Shinichiro Yada | Zendy; Yosuke Kuroda | Zendy; Sadafumi Tamiya | Zendy; Takayuki Matsumoto | Zendy; Eishi Baba | Zendy; Mine Harada | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effective Monotherapy with Amrubicin for a Refractory Extrapulmonary Small-Cell Carcinoma of the Liver

Author(s) -

Taichi Isobe,

Shunichi Yanai,

Hitoshi Kusaba,

Shinichiro Yada,

Yosuke Kuroda,

Sadafumi Tamiya,

Takayuki Matsumoto,

Eishi Baba,

Mine Harada

Publication year - 2009

Publication title -

case reports in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.2

H-Index - 20

eISSN - 1687-9627

pISSN - 1687-9635

DOI - 10.1155/2009/538081

Subject(s) - irinotecan , etoposide , medicine , refractory (planetary science) , chemotherapy , cisplatin , oncology , gastroenterology , cancer , colorectal cancer , physics , astrobiology

Small-cell carcinoma of the liver is a rare neoplasm, and no standard treatment for it has yet been established. A 72-year-old man with an extensive disease stage of small-cell carcinoma of the liver was treated with systemic chemotherapy consisting of cisplatin and etoposide (PE) followed by irinotecan. Although the masses were markedly decreased once after the sixth course of PE, amrubicin monotherapy as third-line chemotherapy was started because the hepatic masses had increased again. The administration of amrubicin was repeated in 8 courses with regression of the disease, resulting in a 26-month survival since the first-line chemotherapy was started. This is the first case report of a refractory EPSCC successfully treated with amrubicin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research